tbuckley/cabot-search huggingface dataset:
163. Baculovirus-Mediated Gene Transfer in New Zealand White Rabbit Skeletal Muscle
Authors: Tommi T. Heikura, Miia M. Roschier, Anssi J. Mahonen, Hanna P. Lesch, Tuomas T. Rissanen, Olli H. Laitinen, Kari J. Airenne, Seppo Yla-Herttuala
Journal: Molecular Therapy (2006)

Therapeutic angiogenesis in ischemic tissues with vascular endothelial growth factors (VEGF) is a promising application of gene therapy. The transient nature of non-integrating vectors such as adenoviruses does not yield permanent therapeutic effect. On the other hand, prolonged VEGF expression by integrating vectors includes the risk of insertional mutagenesis. One way to overcome these obstacles could be combination therapy using two different transient vectors. Dose-response study was performed to evaluate baculovirus tolerance in New Zealand White rabbit skeletal muscle. Secondly, we show the first evidence that baculoviral VEGF-DDNDC gene transfer in healthy skeletal muscle results in statistically significant capillary enlargement compared to both baculovirus and adenovirus b-galactosidase (lacZ) control gene transfers. We also show improved transduction efficiency of baculovirus vector after different modifications of viral genome. In conclusion, both our in vitro and in vivo results suggest baculovirus as potential gene transfer vector. The efficacy of the baculovirus vectors may not reach the adenovirus level but is however sufficient to gain biologically efficient results. This opens promising possibilities regarding combination gene therapy, and should be studied in the future.
Endotherapy for paraduodenal pancreatitis: a large retrospective case series
Authors: Marianna Arvanitakis, Johanne Rigaux, Emmanuel Toussaint, Pierre Eisendrath, Maria Bali, Celso Matos, Pieter Demetter, Patrizia Loi, Jean Closset, Jacques Deviere, Myriam Delhaye
Journal: Endoscopy (2014)

<b>Background and study aims:</b> Paraduodenal pancreatitis is histologically well defined but its epidemiology, natural history, and connection with chronic pancreatitis are not completely understood. The aim of this study was to review the endoscopic and medical management of paraduodenal pancreatitis. <b>Patients and methods:</b> Medical records of all patients with paraduodenal pancreatitis diagnosed by magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasonography (EUS) between 1995 and 2010 were retrospectively reviewed. Clinical features, imaging procedures, and treatments were investigated. The primary end point was the rate of clinical success, and the secondary end points were the radiological or endoscopic improvement, complication rate, and overall survival rate. <b>Results:</b> A total of 51 patients were included in the study (88.2 % alcohol abuse; median age 49 years [range 37 – 70]; 50 men). The most frequent symptoms at presentation were pain (n = 50; 98.0 %) and weight loss (n = 36; 70.6 %). Chronic pancreatitis was present in 36 patients (70.6 %), and 45 patients (88.2 %) had cysts. Other findings included stricture of the pancreatic duct (n = 37; 72.5 %), common bile duct (n = 29; 56.9 %), and duodenum (n = 24; 47.1 %). A total of 39 patients underwent initial endoscopic treatment: cystenterostomy (n = 20), pancreatic and/or biliary duct drainage (n = 19), and/or duodenal dilation (n = 6). For the patients with available follow-up (n = 41), 24 patients required repeat endoscopy and 9 patients required surgery after the initial endoscopic management. After a median follow-up of 54 months (range 6 – 156 months), complete clinical success was achieved in 70.7 % of patients, and the overall survival rate was 94.1 %. <b>Conclusions:</b> This is the largest series concerning the management of paraduodenal pancreatitis using endotherapy as the first-line intervention. Although repeat endoscopic procedures were required in half of the patients, no severe complication was observed and surgical treatment was ultimately needed in less than 25 % of the patients.
Antinuclear antibodies during procainamide treatment and drug acetylation.
Authors: D M Davies, M A Beedie, M D Rawlins
Journal: BMJ (1975)

Acetylator capacity was determined in two groups of patients who had received procainamide for more than three months. In seven patients antinuclear antibodies (A.N.A.) were detected during treatment, and these changes disappeared (in six patients) or were less pronounced (one patient) after withdrawal of the drug. These patients tended to have faster acetylation rates, and five were phenotypically "rapid" acetylators. Five patients who did not develop A.N.A. during treatment had less rapid (P less than 0.05) rates of acetylation, and four were "slow" acetylators. We suggest that the immunological changes which may occur during procainamide treatment may be associated with the acetylated metabolite of procainamide rather than the parent compound and that it might be possible to identify patients at risk.
New UK guidance on industry-health professional collaboration
Authors: B. Mintzes
Journal: BMJ (2012)

If it takes two to tango, let’s not dance

Is collaboration between health professionals and the drug industry a route to better patient care than can be delivered by each party in isolation? This is the central tenet of new UK guidance from the Ethical Standards in Health and Life Sciences Group (ESHLSG), which represents “professional, representative, and regulatory bodies from the health professional community and life sciences industry.”1

The guidance champions a role for the drug industry in professional education. Sales representatives are “a useful source of information” and professionals should not accept “negative myths” of harm to objectivity from industry partnerships. ESHLSG co-chair Simon Jose, president of the Association of the British Pharmaceutical Industry, highlights that the aim of the guidance is to deal with “some reputational …
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Authors: Tara L. Kieffer, Christoph Sarrazin, Janice S. Miller, Martin W. Welker, Nicole Forestier, Hendrik W. Reesink, Ann D. Kwong, Stefan Zeuzem
Journal: Hepatology (2007)

Telaprevir (VX-950) is an orally active, specifically targeted antiviral therapy for hepatitis C virus (HCV) that has been shown to profoundly reduce plasma HCV RNA in genotype 1 patients. Using a highly sensitive sequencing assay that detects minor populations of viral variants (>or=5%), mutations were identified that conferred low-level (V36M/A, T54A, or R155K/T) or high-level (A156V/T and 36/155) resistance to telaprevir in vitro. We report a detailed kinetic analysis of these variants in 16 patients given telaprevir or telaprevir + pegylated interferon-alpha-2a (PEG-IFN-alpha-2a) for 14 days. In 4 patients who had a viral rebound on telaprevir alone, the R155K/T and A156V/T variants were detected during the initial steep decline in HCV RNA. During the rebound phase, the R155K/T and A156V/T variants were replaced by V36(M/A)/R155(K/T) double mutant variants. In the remaining 12 patients given telaprevir alone or with telaprevir/PEG-IFN-alpha-2a, the A156V/T variant was detected in some patients, but viral levels continued to decline in all patients.These studies suggest that the initial antiviral response to telaprevir is due to a sharp reduction in wild-type virus, which uncovers pre-existing telaprevir-resistant variants. In patients given telaprevir alone, viral rebound can result from the selection of variants with greater fitness. However, the combination of telaprevir and PEG-IFN-alpha-2a inhibited both wild-type and resistant variants. In the present study, every patient who began PEG-IFN-alpha-2a and ribavirin after the 14-day dosing period had undetectable HCV RNA levels at 24 weeks, indicating that telaprevir-resistant variants are sensitive to PEG-IFN-alpha-2a and ribavirin.
Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning
Authors: M. Matsuda, T. G Catena, R. S V. Heide, R. B Jennings, K. A Reimer
Journal: Cardiovascular Research (1993)

Journal Article Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning Get access Mitsuo Matsuda, Mitsuo Matsuda Department of Pathology (Box 37121, Duke University Medical Center, Durham, NC 27710, USA: M Matsuda, T G Catena, R S Vander Heide, R B Jennings, K A Reimer. Correspondence to Dr Reimer. Search for other works by this author on: Oxford Academic PubMed Google Scholar Thomas G Catena, Thomas G Catena Department of Pathology (Box 37121, Duke University Medical Center, Durham, NC 27710, USA: M Matsuda, T G Catena, R S Vander Heide, R B Jennings, K A Reimer. Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard S Vander Heide, Richard S Vander Heide Department of Pathology (Box 37121, Duke University Medical Center, Durham, NC 27710, USA: M Matsuda, T G Catena, R S Vander Heide, R B Jennings, K A Reimer. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert B Jennings, Robert B Jennings Department of Pathology (Box 37121, Duke University Medical Center, Durham, NC 27710, USA: M Matsuda, T G Catena, R S Vander Heide, R B Jennings, K A Reimer. Search for other works by this author on: Oxford Academic PubMed Google Scholar Keith A Reimer Keith A Reimer Department of Pathology (Box 37121, Duke University Medical Center, Durham, NC 27710, USA: M Matsuda, T G Catena, R S Vander Heide, R B Jennings, K A Reimer. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 27, Issue 4, April 1993, Pages 585–592, https://doi.org/10.1093/cvr/27.4.585 Published: 01 April 1993 Article history Received: 08 September 1992 Accepted: 22 December 1992 Published: 01 April 1993
An antiidiotypic antibody that recognizes the beta-adrenergic receptor.
Authors: C J Homcy, S G Rockson, E Haber
Journal: Journal of Clinical Investigation (1982)

Antialprenolol rabbit antibodies were fractionated on an acebutolol affinity resin, followed by L-propranolol elution so as to separate a class of binding sites that mimic the beta-adrenergic receptor. Allotype-identicaL rabbits were immunized with this fraction. After 6 mo, antisera exhibited antiidiotypic activity inhibiting [3H]alprenolol binding to the original antibody and to rabbit antiacebutolol antibodies, which had a spectrum of ligand-binding properties identical to the original idiotype. Those antisera demonstrating the original idiotype. Those antisera demonstrating the most potent antiidiotypic activity also blocked [3H]alprenolol binding to the beta-adrenergic receptor of turkey membrane, canine pulmonary membrane, and rat reticulocyte. An idiotype affinity-purified fraction showed similar activity, inhibiting beta-receptor binding with a calculated dissociation constant (KD) of 53 nM. Isoproterenol-mediated adenylate cyclase activity was also inhibited in a competitive manner. The universality of recognition of these antiidiotypic antisera indicate that the three-dimensional structure of a receptor's binding site can be modeled by a subset of an elicited antibody population.
The Internet as a Newly Emerging Risk Environment for Sexually Transmitted Diseases
Authors: Mary McFarlane
Journal: JAMA (2000)

ContextTransmission of sexually transmitted diseases (STDs) such as human immunodeficiency virus (HIV) infection is associated with unprotected sex among multiple anonymous sex partners. The role of the Internet in risk of STDs is not known.ObjectiveTo compare risk of STD transmission for persons who seek sex partners on the Internet with risk for persons not seeking sex partners on the Internet.DesignCross-sectional survey conducted September 1999 through April 2000.Setting and ParticipantsA total of 856 clients of the Denver Public Health HIV Counseling and Testing Site in Colorado.Main Outcome MeasuresSelf-report of logging on to the Internet with the intention of finding sex partners; having sex with partners who were originally contacted via the Internet; number of such partners and use of condoms with them; and time since last sexual contact with Internet partners, linked to HIV risk assessment and test records.ResultsOf the 856 clients, most were white (77.8%), men (69.2%), heterosexual (65.3%), and aged 20 to 50 years (84.1%). Of those, 135 (15.8%) had sought sex partners on the Internet, and 88 (65.2%) of these reported having sex with a partner initially met via the Internet. Of those with Internet partners, 34 (38.7%) had 4 or more such partners, with 62 (71.2%) of contacts occurring within 6 months prior to the client's HIV test. Internet sex seekers were more likely to be men (P<.001) and homosexual (P<.001) than those not seeking sex via the Internet. Internet sex seekers reported more previous STDs (P = .02); more partners (P<.001); more anal sex (P<.001); and more sexual exposure to men (P<.001), men who have sex with men (P<.001), and partners known to be HIV positive (P<.001) than those not seeking sex via the Internet.ConclusionsSeeking sex partners via the Internet was a relatively common practice in this sample of persons seeking HIV testing and counseling (representative of neither Denver nor the overall US population). Clients who seek sex using the Internet appear to be at greater risk for STDs than clients who do not seek sex on the Internet.
REPRODUCIBILITY OF INVASIVELY MEASURED AND NON-INVASIVELY COMPUTED FRACTIONAL FLOW RESERVE
Authors: Sara Gaur, Hiram G. Bezerra, Evald H. Christiansen, Kentaro Tanaka, Jesper M. Jensen, Anne K. Kaltoft, Hans Erik Botker, Jens F. Lassen, Christian J. Terkelsen, Bjarne L. Norgaard
Journal: Journal of the American College of Cardiology (2014)
Definition, Practice, and Teaching of Psychosomatics A Global Survey
Authors: R.A. Ramsay, A.J. Krakowski, E.D. Wittkower, F. Engelsmann
Journal: Psychotherapy and Psychosomatics (1979)

Two sets of overlapping questionnaires were distributed world-wide via college members to 200 psychiatrists and 200 physicians. 50% of psychiatrists (n = 101) and 30% of physicians (n = 63), replied, representing 25 countries. Areas surveyed include definitions of 'psychosomatics', physician-psychiatrist attitudes, liaison activities, teaching patterns and methods, and professional affiliation of respondents. Comparative statistical analysis of the two groups reveals significant response differences in certain conceptualizations of 'psychosomatics' and in the diagnostic distribution of referred patients. Cross-continental comparisons revealed greater acceptance of the term 'psychosomatics' by respondents from Asia, differences between North American and European conceptualizations, and a stronger attachment of the field in the Far East to academic departments of medicine as compared with the West.
Ensuring Access to the Appropriate Health Care Professionals
Authors: Scott A. Lorch
Journal: JAMA Pediatrics (2014)

12. Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth onmaternal and infant outcomes. Cochrane Database Syst Rev. 2012;8:CD003248. 13. Ghavam S, Batra D, Mercer J, et al. Effects of placental transfusion in extremely low birthweight infants: meta-analysis of longand short-term outcomes. Transfusion. 2014;54(4):1192-1198.
Natalizumab Use During the Third Trimester of Pregnancy
Authors: Aiden Haghikia, Annette Langer-Gould, Georg Rellensmann, Henriette Schneider, Tobias Tenenbaum, Birte Elias-Hamp, Sylvia Menck, Julian Zimmermann, Sandra Herbstritt, Martin Marziniak, Tania Kümpfel, Ingrid Meinl, Tatiana Plavina, Ralf Gold, Kerstin Hellwig
Journal: JAMA Neurology (2014)

Natalizumab reduces multiple sclerosis relapses very effectively; however, severe disease activity may return once natalizumab treatment is withdrawn, as recommended during pregnancy. Sometimes restarting natalizumab treatment may be the best option for the mother, but the consequences for the infant are unknown. Except for a few single case reports, to our knowledge, comprehensive data about third-trimester natalizumab exposure are scant.In a case series of 12 women with 13 pregnancies and highly active multiple sclerosis who were treated with natalizumab during their third trimester of pregnancy, we assessed the clinical and laboratory effects on the newborns. We observed mild to moderate hematologic alterations in 10 of 13 infants including thrombocytopenia and anemia. In a subsample of 5 mother-child pairs, we analyzed natalizumab levels in the umbilical cord blood. Natalizumab was detectable in all 5 newborns.Natalizumab can be a therapeutic option in patients with highly active multiple sclerosis during pregnancy. We recommend that a pediatrician be available at the time of delivery to evaluate for potential complications of anemia and thrombocytopenia in newborns exposed to natalizumab during the third trimester.
The association of coronary heart disease and outcome following carotid endarterectomy: A population-based study in olmsted county, Minnesota, 1970–1988
Authors: Charanjit S. Rihal, Bernard J. Gersh, Jack P. Whisnant, Thom W. Rooke, Thoralf M. Sundt, W.Michael O'Fallon, David J. Ballard
Journal: Journal of the American College of Cardiology (1991)
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine
Authors: Alina F. Dumitru, Mohamed Shamji, Martin Wagenmann, Simone Hindersin, Kathrin Scheckenbach, Jens Greve, Thomas Klenzner, Lorenzo Hess, Sabine Nebel, Christian Zimmermann, Catherine Zahner, Carsten B. Schmidt-Weber, Adam M. Chaker
Journal: Journal of Allergy and Clinical Immunology (2011)
Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2’-deoxycytidine
Authors: Jason A. Dubovsky, John J. Powers, Yang Gao, Luis F. Mariusso, Eduardo M. Sotomayor, Javier A. Pinilla-Ibarz
Journal: Cancer Research (2011)

Abstract T cell immune dysfunction has an important role in the profound immunosupression that characterizes chronic lymphocytic leukemia (CLL). Improper polarization of T cells has been proposed as one of the mechanism involved. Mounting data implicates chromatin regulation, namely promoter methylation, in the plasticity of naïve human T cells. Recent in-vitro evidence indicates that this plasticity may be phenotypically altered by using methylation inhibitors which are approved for clinical use in certain types of cancer. These results beg the question: can the ineffective polarization of T lymphocytes in the context of CLL be effectively modulated using methylation inhibitors in a sustainable therapeutic fashion? To answer this question our laboratory has studied the effects of 5-aza-2’-deoxycytidine (5A2) in helper and cytotoxic T lymphocytes from healthy donors and CLL patients in well characterized molecular and epigenetic signaling pathways involved in effective polarization. Moreover, we sought to investigate the consequences of methylation inhibitor treatment on lymphocyte survival, activation intensity, and naïve cell polarization. Our data indicates that 5A2 treatment can repolarize Th2 cells to effectively secrete interferon gamma, signal via T-bet, and achieve demethylation of critical Th1 specific promoters. Moreover, we demonstrate that 5A2 can force Th1 polarization of naïve T cells despite a strong IL-4 stimuli and a lack of IL-12. In conclusion our data seeks to define a modality in which improper or ineffective T cell polarization can be altered by 5AZA and could be incorporated in future therapeutic interventions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5526. doi:10.1158/1538-7445.AM2011-5526
Long-term adherence to evidence-based therapies for coronary artery disease and heart failure in the outpatient setting
Authors: Nancy M. Allen LaPointe, Judith M. Kramer, Bradley G. Hammill, Anita Chen, Elizabeth R. DeLong, Richeille K. Ricketts, Lawrence H. Muhlbaier, Charles B. McCants, Robert M. Califf
Journal: Journal of the American College of Cardiology (2003)
Does influenza vaccination induce bullous pemphigoid? A report of four cases
Authors: None Downs, None Lear, None Bower, None Kennedy
Journal: British Journal of Dermatology (1998)

Journal Article Does influenza vaccination induce bullous pemphigoid? A report of four cases Get access A.M.R. Downs, A.M.R. Downs Department of Dermatology, Bristol Royal Infirmary, Bristol BS2 8HW, U.K. Search for other works by this author on: Oxford Academic Google Scholar J. Lear, J. Lear Department of Dermatology, Bristol Royal Infirmary, Bristol BS2 8HW, U.K. Search for other works by this author on: Oxford Academic Google Scholar C.P.R Bower, C.P.R Bower Department of Dermatology, Bristol Royal Infirmary, Bristol BS2 8HW, U.K. Search for other works by this author on: Oxford Academic Google Scholar C.T.C. Kennedy C.T.C. Kennedy Department of Dermatology, Bristol Royal Infirmary, Bristol BS2 8HW, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 138, Issue 2, 1 February 1998, Page 363, https://doi.org/10.1046/j.1365-2133.1998.02097.x Published: 01 February 1998
Ultrasound and Mammography for Breast Cancer Screening
Authors: Nehmat Houssami
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Approach to Information Handling in General Practice
Authors: K. A. Harden, R. McG. Harden, D. Reekie
Journal: BMJ (1974)

In this paper we describe the use of punched feature cards in a general practice for 18 months. Its advantages are the low cost, speed of information retrieval, visible statistics, computer compatibility, accuracy, confidentiality, flexibility, and simplicity of setting up and collection of information. The system encourages the doctor to ask questions about his practice, and could readily be adopted in other practices.